Guggenheim raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $124 from $115 and keeps a Buy rating on the shares, primarily driven by an increase to the firm’s Cortrophin sales estimates following ANI’s preliminary Q4 results and 2026 outlook earlier this week.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
- ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
- ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’
- ANI Pharmaceuticals Announces Leadership Transition in Board
- ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed